Synergistic effects of pravastatin and pioglitazone in renal tubular epithelial cells induced by transforming growth factor-β1

Authors

  • Jia-li Wei,

    1. Department of Cardio, Renal and Cerebrovascular Medicine, Faculty of Medicine, Kagawa University, Kagawa, Japan
    Search for more papers by this author
    • These authors contributed equally to this work.

  • Chun-yang Ma,

    1. Department of Neurosurgery, The Affiliated Hospital of Hainan Medical College, Longhua Road, Haikou, Hainan 510008, P.R. China
    Search for more papers by this author
    • These authors contributed equally to this work.

  • Yang-De Zhang,

    Corresponding author
    1. National Key Laboratory of Nanobiological Technology, Ministry of Health, Changsha 410008, China
    Search for more papers by this author
  • Yiming Li

    Corresponding author
    1. Department of Physiology, School of Medicine, Xi'an Jiaotong University, Xi'an, P.R. China
    Search for more papers by this author

Corresponding author. Tel.: +8613907310192. jlwei525@yahoo.com.cn

Corresponding author. Tel.: +8613907310192. lymedu@yahoo.com.cn

Abstract

Recent studies suggest that treatment with PPAR-γ agonists and statins have beneficial effects on renal disease. However, the combined effects of PPAR-γ agonists and statins in human renal epithelial cells are unknown. Our present study revealed that there were synergistic effects of pravastatin and pioglitazone in the expression of alpha-smooth muscle actin (α-SMA), connective tissue growth factor (CTGF), fibronectin (FN), plasminogen activator inhibitor-1 (PAI-1) and collagen 1 in human renal proximal tubular epithelial cells induced by transforming growth factor-beta 1 (TGF-β1). The beneficial effects of combined therapy against renal tubular epithelial cell injury are attributed, at least in part, to the inhibition of transdifferentiation, extracellular matrix deposition and cytokine production.

Ancillary